4142:TPE
Adimmune Corp
NT$१६.३५
arrow_downward
-१.५१%(-०.२५) १ दि
६ नोव्हें, १:३०:०४ PM [GMT]+८ · TWD
search
सर्व सिम्बॉल
| सिम्बॉल | किंमत | बदल | % बदल |
|---|
insights_auto4142 साठी टॉप इनसाइट जनरेट करत आहे...
उघडा
NT$१६.०५
उच्च
NT$१६.५०
कमी
NT$१५.६५
मार्केट कॅप
७.०२ अब्ज
सरासरी उलाढाल
१०.७६ लाख
उलाढाल
२१.५९ लाख
५२ आठवड्यांतील उच्चांक
NT$२२.५०
५२ आठवड्यांतील नीचांक
NT$१५.६५
EPS
-NT$०.३४
थकित शेअर
२३.५३ कोटी
कर्मचाऱ्यांची संख्या
५६४
उघडा
NT$१६.०५
उच्च
NT$१६.५०
कमी
NT$१५.६५
मार्केट कॅप
७.०२ अब्ज
सरासरी उलाढाल
१०.७६ लाख
उलाढाल
२१.५९ लाख
५२ आठवड्यांतील उच्चांक
NT$२२.५०
५२ आठवड्यांतील नीचांक
NT$१५.६५
EPS
-NT$०.३४
थकित शेअर
२३.५३ कोटी
कर्मचाऱ्यांची संख्या
५६४
बातम्यांच्या स्टोरी
वेब स्रोत आणि बातमी भागीदारांकडून
Yahoo Finance
·
१ तासापूर्वी
Nasdaq Stock Market Correction: 3 Words From Warren Buffett To Remember RIght Now
Benzinga
·
४३ मिनिटांपूर्वी
Nasdaq Tumbles 5.5% as AI Stocks Crater: Investor Sentiment Weakens, Fear & Greed Index Moves to ‘Extreme
FXStreet
·
३७ मिनिटांपूर्वी
Nasdaq in free fall, semiconductors crash 12% – Short-term bounce or more pain ahead? [Video]
The Motley Fool
·
५ तासांपूर्वी
The Nasdaq Plunges 5%. What the Data Center Crash Means for Investors
प्रोफाइल
Adimmune Corporation is a Taiwanese pharmaceutical company engaged in the research, development, manufacturing, and sales of medicines and vaccines for both humans and animals. Its products are supplied to both local and international markets.
Founded in 1965 and headquartered in Tanzi District, Taichung, it has a market cap of US$230 million, 564 employees and annual sales of $106 million as of 2026.
Adimmune continues to seek expansion its role in the regional pharmaceutical and vaccine industry through international collaborations.
In January 2021, Adimmune Corporation announced a partnership with Sam Chun Dang Pharm to jointly develop an injectable medication used to treat macular disease.
In July 2021, the company announced that its first overseas manufacturing site will be situated in the Special Economic Zone in East Java, Indonesia, aiming to launch clinical trials for its COVID-19 vaccine in Indonesia early 2022.
In August 2021, Adimmune Corporation signed a memorandum of understanding with Becton, Dickinson and Company to strengthen its international pharmaceutical collaboration. Wikipedia
Adimmune Corp बद्दल